A group of prominent AIDS activists is urging the New York attorney general to investigate Gilead Sciences (GILD) for potential antitrust violations in connection with deals the drug maker struck with rivals that sought to sell generic versions of a best-selling HIV treatment.

The activists are concerned Gilead may have reached agreements with the companies that allow it to improperly forestall competition to its Truvada HIV prevention pill, according to an Aug. 4 letter they wrote to Eric Schneiderman, the New York attorney general. Those deals were reached three years ago to settle patent litigation and generic versions are not expected to appear before 2021.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Sorry to disappoint the AIDS activists, but TEVA holds the only ANDA for Truvada. If they remain as the single source generic they will be free to charge almost as much as Gilead, and with 180 day exclusivity will reap at least $1,000,000,00 in sales, assuming TEVA is still around in a few years.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy